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Abstract: Tumor immune escape is associated with the loss of tumor HLA class I (HLA-I)
expression commonly found in malignant cells. Accumulating evidence suggests that the efficacy
of immunotherapy depends on the expression levels of HLA class I molecules on tumors cells.
It also depends on the molecular mechanism underlying the loss of HLA expression, which could
be reversible/“soft” or irreversible/“hard” due to genetic alterations in HLA, β2-microglobulin
or IFN genes. Immune selection of HLA-I negative tumor cells harboring structural/irreversible
alterations has been demonstrated after immunotherapy in cancer patients and in experimental
cancer models. Here, we summarize recent findings indicating that tumor HLA-I loss also correlates
with a reduced intra-tumor T cell infiltration and with a specific reorganization of tumor tissue. T cell
immune selection of HLA-I negative tumors results in a clear separation between the stroma and the
tumor parenchyma with leucocytes, macrophages and other mononuclear cells restrained outside the
tumor mass. Better understanding of the structural and functional changes taking place in the tumor
microenvironment may help to overcome cancer immune escape and improve the efficacy of different
immunotherapeutic strategies. We also underline the urgent need for designing strategies to enhance
tumor HLA class I expression that could improve tumor rejection by cytotoxic T-lymphocytes (CTL).
Keywords: HLA class I loss; tumor infiltrating lymphocytes (TILs); tumor immune escape
1. Introduction
There is a general consensus among immunologists that tumor cells can be recognized and
destroyed by CD8+ T lymphocytes in vitro and in vivo. Data obtained from different groups
support this concept [1–3]. Tumor antigens are presented to CTLs as small peptides via Major
Histocompatibility Complex class I molecules (MHC-I, or HLA-I in humans) [4]. It is likely that
T cell-mediated immune surveillance is, in fact, destroying nascent tumors during our life time without
any noticeable signs of the rejection process. Nevertheless, tumors grow and metastasize without any
visible immune control. Different tumor-immune escape mechanisms have been described that could
explain the paradox of the absence of a CTL-mediated tumor rejection and the existence of tumor
peptides recognized by CD8+ T cells [5].
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HLA-I loss or downregulation is one of the tumor escape mechanisms widely used by cancer
cells to evade T cell-mediated immune destruction [6–9]. Our laboratory has been analyzing in detail
different HLA-I-altered phenotypes in human tumors [10] and we have proposed that the molecular
mechanism responsible for the HLA-I loss predetermines the possibility to recover normal HLA-I
expression and the success of T cell-mediated immunotherapy [11,12]. When the underlying molecular
mechanism is reversible, any immunotherapy may activate the release of TH1 type cytokines in
the tumor microenvironment, leading to upregulation of HLA-I expression and facilitating tumor
rejection. In contrast, if the molecular mechanism is irreversible/“hard”, caused by mutations or Loss
of Heterozygosity (LOH) in chromosomes 6 or 15, tumor cells are likely to remain HLA-I negative and
subsequently escape immune rejection. This review summarizes these findings, focusing on the newly
described association between tumor “rejection” or “escape” phenotypes and corresponding changes
observed in tumor tissue architecture.
2. Tumor Immune Escape and HLA Class I Loss
Evidence obtained from different laboratories, including ours, indicate that HLA-I loss is
a frequent finding in human primary tumors and in metastases [13,14]. Due to the complexity
of the HLA genetic system and the difficulties in measuring the HLA-I expression in human tissue,
the available information on tumor HLA-I expression does not always reflect the real pattern and
the character of HLA-I alterations [15]. Additional detailed analysis is required to obtain a more
accurate picture of HLA-I defects and the underlying molecular mechanisms in a given type of
cancer. It is important to keep in mind that initially most tumors are HLA-I positive and the specific
T cell-mediated immune reaction should be able to destroy these aberrant cells [13]. This process,
called “T-cell immune selection”, generates tumors with a different ratio of HLA-I positive and
-negative cancer cells depending on the strength of the immune response [16]. In 1996, our laboratory
organized an “HLA and Cancer” component of the International HLA workshop [9]. One of the
major tasks of the component was to establish criteria to classify HLA expression in tumor tissues as
HLA-I positive (more that 75% cells stained), heterogeneous (between 25% and 75% of cells stained),
and HLA-I negative (less than 25% HLA-I positive tumor cells). This tumor classification is in
concordance with a progressive immune selection of HLA-I negative tumor variants with successive
formation of tumor lesions mainly composed of HLA-I negative cancer cells [17]. In this context,
published observations that HLA-I expression in pancreatic and lung cancer inversely correlates with
the degree of tumor infiltration with lymphocytes, suggests an active T cell-mediated immune selection
in human tumors [18,19].
3. T Cell Immune Selection of MHC Class I Negative Tumor Variants
As indicated earlier, T cell-mediated immune response is an important mechanism of the
destruction of HLA-I positive tumor cells [20]. At the same time, this response is also the mechanism
of selection of HLA-I negative tumor variants. There is accumulating evidence that T cell immune
selection certainly plays an important role in the outgrowth of the MHC/HLA-I negative tumor
variants [16,17,21]. We have previously reported that a mouse fibrosarcoma tumor clone (which is
MHC-I negative in baseline conditions, but inducible by IFN-gamma), produces “MHC-I positive”
spontaneous lung metastasis in immunodeficient nude/nude mice lacking T-cell, while in syngeneic
immunocompetent mice it generates “MHC-I negative” metastases [22]. In other mouse models, it has
been demonstrated that positive tumor MHC-I expression correlates with tumor immunogenicity and
serves as a key predictive marker of the response to immunotherapy [23].
4. Immunotherapy Selects Tumor Cells with Irreversible/“Hard” HLA-I Lesions
The analysis of different subcutaneous metastases obtained from a melanoma patient with mixed
response to immunotherapy showed that regression or progression of metastatic lesions is associated
with the presence of HLA-I molecules on the tumor cell surface [24–26]. Melanoma lesions with high
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HLA-I expression level were heavily infiltrated by CD4+ and CD8 positive T cells and were rejected.
In contrast, metastatic lesions with low HLA-I expression were resistant to immunotherapy and
progressed. These findings strongly suggest that immunotherapy induces tumor HLA-I upregulation
and rejection of cancer cells with “reversible/soft lesions” [12] (Figure 1). Similar results were obtained
in spontaneous metastases induced in a mouse fibrosarcoma [22]. In this context, it has been recently
reported that the recurrent lesions in four melanoma metastatic patients treated with monoclonal
antibodies directed against “immune checkpoint” molecules harbor mutations in β2-microglobulin
and IFN genes, confirming the idea that different types of immunotherapy can activate T cell-mediated
immune response and select tumor cells with irreversible/“hard” lesions [27] (Figure 1). IFNs and other
TH1 type cytokines undoubtedly play a major role in the upregulation of tumor MHC-I expression
and in the activation of antigen presentation, ultimately leading to tumor rejection [28,29].
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treatments, including IL-2, Bacillus Calmette–Guérin (BCG), or tumor peptides, can boost anti-tumor 
T cell-mediated responses. Currently, monoclonal antibodies against “immune checkpoint” 
molecules are also being actively used in the clinic. All these therapies can modify the tumor 
microenvironment and induce the release of TH1 type cytokines. HLA-I deficient tumors can 
upregulate HLA-I expression depending on the nature of the underlying molecular alteration. If the 
defect is reversible/“soft”, tumor or metastatic lesion can be rejected after cytokine-mediated recovery 
of the antigen presentation capacity. If the alteration is irreversible/“hard”, tumor or metastasis will 
remain HLA-I negative and, most likely, will escape T cell responses and continue to grow. 
5. Changes in Stromal/Tumor Tissue Organization and HLA Class I Loss 
We have recently obtained evidence indicating that tumor tissue architecture changes dramatically 
with HLA-I loss during cancer progression [13,18]. In lung cancer HLA-I expression strongly 
correlates with lymphocyte/macrophage infiltration pattern and tumor tissue organization reflecting 
how an immune-privileged compartment with ineffective anti-tumor immunity is generated during 
cancer development. These changes also affect the pattern of leucocyte infiltration and its localization 
within or outside the tumor area. We have classified these phases or types of tumor tissue 
organization as follows: permissive Phase I with HLA-I positive/heterogeneous expression pattern 
and tumor infiltrating lymphocytes (TILs); and encapsulated/non-permissive Phase II with HLA-I 
negative tumor cells and peritumoral localization of leucocytes and other immune cells [18]. 
5.1. A Permissive Tumor Tissue Structure Observed in HLA-I Positive Tumors (Phase I) 
When a tumor is HLA-I positive or heterogeneous, it is infiltrated with lymphocytes and 
macrophages owing to an immune-permissive tumor microenvironment (TME), in which tumor and 
TILs are in close contact with each other allowing recognition and destruction of the target tumor 
cells (Figure 2a). Tumors are infiltrated by CD4+ and CD8+ lymphocytes and by other 
leucocytes/macrophages at various degrees depending on the HLA-I positive/negative tumor cell 
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ratio within the heterogeneous tumor mass. HLA-I expression was found to be correlated with intra-
or peritumoral distribution of CD8+ T lymphocytes, which, in turn, is associated with different phases
of tumor evolution, distinct tissue reorganization patterns and different M1/M2 ratios. HLA-I positive
tumor cells are actively killed by CTLs in phase I, leading to a progressive T-cell immune selection of
HLA-I deficient tumor cells (phase II).
Vaccines 2017, 5, 7  4 of 10 
 
ratio within the heterogeneous tumor mass. HLA-I expression was found to be correlated with intra- 
or peritumoral distribution of CD8+ T lymphocytes, which, in turn, is associated with different phases 
of tumor evolution, distinct tissue reorganization patterns and different M1/M2 ratios. HLA-I positive 
tumor cells are actively killed by CTLs in phase I, leading to a progressive T-cell immune selection of 
HLA-I deficient tumor cells (phase II). 
 
(a) HLA-I Positive Tumor 
 
(b) HLA-I Negative Tumor 
Figure 2. (a) Tissue architecture in HLA-I positive tumors (Phase I). Tumor tissue samples obtained 
from a patient diagnosed with non-small cell lung cancer (NSCLC) were immunostained with 
monoclonal antibodies against HLA-I, β2-microglobulin, HLA class II, CD8, CD3, and CD45 
molecules. Most of the cancer cells are HLA-I positive and remain in close contact with HLA-I positive 
immune cells. The tissue structure is “permissive”, allowing TILs to enter the tumor mass, producing 
a significant CD8+ infiltration, and permitting a direct contact with cancer cells. Tumor parenchyma 
and stroma cannot be distinguished when immunostained for HLA-I expression. This tissue 
organization pattern in HLA-I positive tumors differs from that observed in HLA-I negative tumors 
depicted in Figure 2b; (b) Tissue architecture in HLA-I negative tumors (Phase II). In contrast to Figure 
2a, this lung cancer tissue, obtained from another patient, is negative for both HLA-I and -II. T cells 
and other leukocytes are restricted exclusively to the peritumoral stroma that surrounds the tumor 
nest in a “non-permissive” tissue structure. There is a clear separation between tumor parenchyma 
Figure 2. (a) Tissue architecture in HLA-I positive tumors (Phase I). Tumor tissue samples obtained from
a patient diagnosed with non-small cell lung cancer (NSCLC) were immunostained with monoclonal
antibodies against HLA-I, β2-microglobulin, HLA class II, CD8, CD3, and CD45 molecules. Most of
the cancer c ll are HLA-I positive and remain in close contact with HLA-I positive immune cells.
The tissue structure s “permissive”, allowing TILs o enter the tumo ma s, producing a significant
CD8+ infiltration, and permi ting a direct contact with cancer cells. Tumor parenchyma and stroma
cannot be distinguished when immunostained for HLA-I expression. This tissue organization pattern
in HLA-I positive tumors differs from that observed in HLA-I negative tumors depicted in Figure 2b;
(b) Tissue architecture in HLA-I negative tumors (Phase II). In contrast to Figure 2a, this lung cancer
tissue, obtained from another patient, is negative for both HLA-I and -II. T cells and other leukocytes are
restricted exclusively to the peritumoral stroma that surrounds the tumor nest in a “non-permissive”
tissue structure. There is a clear separation between tumor parenchyma and surrounding stroma.
Tumor nodes are composed exclusively of HLA-I negative tumor cells without any infiltrating immune
cells (phase of “immunological silence”).
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5.2. Encapsulated Tumor Nodes Observed in HLA-I Negative Tumors (Phase II)
Phase II is characterized by the lack of tumor infiltrating cells and a clear separation
between HLA-I negative tumor and HLA-I positive stroma cells. It is very likely that due to
the low cytotoxic activity of CD8+ T lymphocytes and the absence of natural killer (NK) cells,
in “phase II” the host is trying to isolate tumor cells from the rest of the body, while tumor cells
are actively creating an immunosuppressive microenvironment by inducing stromal reorganization
and generation of a structure similar to a TH2 granuloma [30]. As a result, tumor architecture changes,
generating tumor nodes surrounded by different types of T-cells/leucocytes/macrophages and
probably other elements of the tumor microenvironment, including Tregs and MDSCs. Furthermore,
this phase is also characterized by a marked peritumoral localization of fibroblasts and alternatively
activated macrophages providing a physical barrier and forming a “non-permissive” tissue structure
(Figure 2b) [18]. Such tumor tissue organization can be observed in a variety of tumors of different
histological type [8], however it has not been previously associated with the absence of HLA-I
expression in tumors. Such an encapsulated HLA-I negative tumor without activated tumor infiltrating
immune cells (phase II) represents a condition of “immunological silence”.
6. Progressive Exclusion and/or Inactivation of NK and CD8+ T Cells from the Distant
Non-Tumor Tissue (DNTT) to the Tumor Tissue (TT)
We have observed significant gradual changes in the composition of the inflammatory infiltrate
in three different areas of cancerous lung tissue: tumor tissue (TT), tissue adjacent to the tumor
(TAT), and distant non-tumor tissue (DNTT) [31]. Using a combination of flow cytometry and
tumor tissue immunohistology, we found a considerable prevalence of activated CD8+DR+ T cells of
effector-memory phenotype in tumor tissues (TT) as compared to TAT and DNTT areas. At the same
time, we observed a remarkable gradual increase in the numbers of T-reg cells from the DNTT area
towards TT (Figure 3) along with a reduction of the CD8/Treg and Th1/Treg ratio in tumor tissue
as compared to a healthy counterpart. The anti-tumor CD8+ T cell-mediated cytotoxicity may be
insufficient due to the increased presence of Treg cells and high frequency of CD8+ cells expressing
CD39 (a marker associated with immunological exhaustion and paracrine inhibition of IFN-γ). In fact,
CD39+ cells have been found to be highly represented in both CD4+ and CD8+ subpopulations in
tumor tissues and were linked to immunosuppressive functions [32]. We favor the idea that the
most important factor reducing the cytotoxic potential of CD8+ T-cells is associated with the lack
of a “direct contact” with HLA-I negative target tumor cells due to an exclusive localization in the
“stroma”, which creates a physical barrier between the HLA-I negative tumor cells and the infiltrating
leucocytes/macrophages (see Figure 2b). In our study, using flow cytometry analysis of the cellular
suspension obtained from the lung tumor samples, we observed that increase in the level of tumor
infiltrating lymphocytes correlates with the increase in the proportion of Tregs (p = 0.012, R = 0.443) and
CD8+CD39+ immunosuppressive cells (p = 0.015, R = 0.489) in this infiltrate. CD39 is an ectoenzyme,
which serves as an integral component of the suppressive machinery of Tregs, inactivating and
converting extracellular ATP into adenosine and allowing the immune escape of tumors. However,
the high level of CD39 expression in both, CD4+ and CD8+ T cells, causes inhibition of the adhesion
molecule expression necessary for transendothelial migration into the tumor and may explain the lack
of infiltrating T-CD8 cells in the tumor nests [33].
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ltogether, the obtained results indicate that tumor nests are poorly infiltrated with NK cells, and even
the small percentage of these cells detecte within the tumor mass do not seem to have a cytotoxic
potential to reject a tumor. Similar enrichment wit CD56bright CD16− NK cells has been reported
in NSCLC tumors [34]. Prevalence of the CD56+ CD16− NK subset with pro-angiogenic activity
favoring tumor development and increased expression of inhibitory receptors in tumor infiltrating
NK cells was reported in other types of cancer [35,36]. Lung adenocarcinoma cells frequently lose
HLA-I expression [18] and theoretically should be heavily infiltrated by NK cells capable of eliminating
HLA-I negative tumor cells. However, NK cells are rarely detected in the lung tumor infiltrate.
Our findings point to the existence of alternative immune escape mechanisms influencing NK cells,
such as (a) difficulty of homing, which translates to the practical exclusion of NK cells by cancer cells;
(b) a progressive alteration in the phenotype of NK cells from healthy tissue to tumor tissue, with the
emergence of a non-cytotoxic phenotype; in tumor tissue, we found a prevalence of CD56 bright CD16
negative non-cytotoxic cytokine-producing NK cells and detected non-cytotoxic CD56/CD16 negative
cells with immature phenotype; and (c) the location of scarce NK cells in the tumor stroma without
a direct contact with cancer cells (particularly in HLA-I negative tumors). Altogether, these results
suggest that the observed changes are induced by the tumor microenvironment which locally impairs
NK homing and differentiation, rendering these cells less cytotoxic and favoring the immune escape of
HLA-I negative tumors.
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Figure 4. Changes in the percentage of CD56bright CD16− NK cells with impaired cytotoxic activity
in different areas of the tumor and “normal” adjacent tissues analyzed by flow cytometry. TT is
enriched by CD56bright CD16− NK cells, the percentage of which gradually increases from DNTT to
TT. DNTT—distant non tumor tissue, ATT—adjacent tumor tissue, TT—tumor tissue. Tumor samples
were obtained from primary lung tumors of non-treated patients by excision of a tumor mass fragment.
ATT samples were taken from tumor-adjacent lung tissue located at approximately 1 cm from the
periphery of the tumor without macroscopic signs of a tumor. DNTT and ATT samples were thoroughly
analyzed to guarantee the complete absence of epithelial tumor cells. The NK cell subset was
determined by the selection of CD45+ CD3− CD20− cells in the FSClow/SSClow gate and calculated as
a percentage of all NK cells [31].
7. Conclusions
There is accumulating evidence that tumor immune escape associated with MHC/HLA-I loss
is a frequent phenomenon observed in human and experimental tumors. We have recently obtained
data suggesting that the location of tumor infiltrating lymphocytes (TILs) in humans is associated
with a particular tumor tissue organization. At the beginning of the T cell-mediated immune
response, CD8+ T lymphocytes enter the tumor tissue and destroy HLA-I positive tumor cells
(a permissive Phase I). Later, as a result of T cell immune selection, HLA-I negative tumor cell variants
appear, ultimately generating a tumor composed only of HLA-I negative cells (Phase II). In this
phase T lymphocytes and other leucocytes/macrophages reside outside the tumor nest. Such tissue
structure provides a biological barrier between the tumor and stroma (a non-permissive Phase II).
This well-established “tumor-parenchyma”-stroma architecture has been identified decades ago,
but has never been linked to tumor HLA-I loss. We favor the idea that this reorganization of tumor
tissue structure during cancer development is associated with the T-cell immune selection of MHC-I
negative tumor cell variants and probably can be observed frequently since the percentage of human
tumors with HLA-I loss reaches 65%–90% in different types of malignancy [8]. These figures are
probably underestimated due to the difficulties in detailed analysis of HLA expression in tumor
tissues. The expression of HLA-I molecules in the tumor cell surface could play a leading role in
directing and conducting the TH1 response until the total elimination of transformed cells. In some
patients, the appearance of HLA-I negative tumor variants as a result of immune escape from T cell
responses may generate tumors composed only of HLA-I negative cells lacking tumor infiltration with
immune cells and encapsulated by the stroma (“immunological silence”). The status of MHC/HLA-I
expression in tumor samples could represent the “driving force” that determines tumor evolution:
either a TH1-mediated tumor rejection or formation of TH2-type granuloma. The recovery of HLA-I
expression in tumors is a major task for the future, since MHC/HLA molecules are playing a key role
in antigen presentation and tumor rejection [12,37,38].
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